Form 4 holding
Director
Natera, Inc.
- Security class
- Common Stock
- Shares / value
- 1,550,280
- Estimated value
- $219,225,094
- Report date
- 25 Apr 2025
- Price
- $141.41
- Ownership
- by Sofinnova Venture Partners IX, L.P.
James Healy
Insider Reports History
- Reporting-owner location
- Menlo Park, CA
- Latest reporting-owner signature
- /s/ Lana Gladstein, Attorney-in-Fact
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for James Healy
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Common Stock
- Shares / value
- 2,227,124
- Estimated value
- $40,088,232
- Report date
- 27 Sep 2024
- Price
- $18.00
- Ownership
- Sofinnova Venture Partners XI, L.P.
Form 4 holding
Director
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 1,863,327
- Estimated value
- $18,596,003
- Report date
- 01 Jul 2024
- Price
- $9.98
- Ownership
- By Sofinnova Venture Partners XI, L.P.
Form 4 holding
Director
Natera, Inc.
- Security class
- Common Stock
- Shares / value
- 46,260
- Estimated value
- $6,541,626
- Report date
- 25 Apr 2025
- Price
- $141.41
- Ownership
- Direct
Form 4 holding
Director
ArriVent Biopharma, Inc.
- Security class
- Common Stock
- Shares / value
- 1,696,752
- Estimated value
- $6,193,145
- Report date
- 30 Jan 2024
- Price
- $3.65
- Ownership
- Sofinnova Venture Partners XI, L.P.
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Common Stock
- Shares / value
- 26,497
- Estimated value
- $476,946
- Report date
- 27 Sep 2024
- Price
- $18.00
- Ownership
- CRESTLINE SUMMIT PINNACLE MASTER, L.P.
Form 4 holding
Director
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 40,851
- Estimated value
- $407,693
- Report date
- 01 Jul 2024
- Price
- $9.98
- Ownership
- By Crestline Summit Master, SPC - PEAK SP
Form 4 holding
Director
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 39,661
- Estimated value
- $395,817
- Report date
- 01 Jul 2024
- Price
- $9.98
- Ownership
- By CRESTLINE SUMMIT PINNACLE MASTER, L.P.
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Common Stock
- Shares / value
- 21,814
- Estimated value
- $392,652
- Report date
- 27 Sep 2024
- Price
- $18.00
- Ownership
- Crestline Summit Master, SPC - PEAK SP
Form 4 holding
Director
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 33,114
- Estimated value
- $330,478
- Report date
- 01 Jul 2024
- Price
- $9.98
- Ownership
- By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Common Stock
- Shares / value
- 18,353
- Estimated value
- $330,354
- Report date
- 27 Sep 2024
- Price
- $18.00
- Ownership
- CRESTLINE SUMMIT MASTER, SPC - CRESTLINE SUMMIT APEX SP
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Common Stock
- Shares / value
- 11,113
- Estimated value
- $200,034
- Report date
- 27 Sep 2024
- Price
- $18.00
- Ownership
- Sofinnova Synergy Master Fund LP
Form 4 holding
Director
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 18,641
- Estimated value
- $186,037
- Report date
- 01 Jul 2024
- Price
- $9.98
- Ownership
- By Sofinnova Synergy Master Fund LP
Form 4 holding
Director
Karuna Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 18 Mar 2024
- Price
- $330.00
- Ownership
- By Sofinnova Management X, L.P.
Form 4 holding
Director
Karuna Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 18 Mar 2024
- Price
- $330.00
- Ownership
- By Sofinnova Synergy Master Fund, LP
Form 4 holding
Director
Karuna Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 18 Mar 2024
- Price
- $330.00
- Ownership
- By Sofinnova Venture Partners X, LP
Form 4 holding
Director
Karuna Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 18 Mar 2024
- Price
- $330.00
- Ownership
- Direct
Form 4 holding
Director
Karuna Therapeutics, Inc.
- Security class
- Option (right to buy)
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 18 Mar 2024
- Price
- $92.30
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Y-mAbs Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 16 Sep 2025
- Price
- $8.52
- Ownership
- Direct
Form 4 holding
Director
Y-mAbs Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 16 Sep 2025
- Price
- $8.60
- Ownership
- Indirect
Form 4 holding
Director
Seaport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 2,731,538
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- By Sofinnova Venture Partners XI, L.P.
Form 4 holding
Director
Coherus BioSciences, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 27,000
- Estimated value
- Report date
- 07 Jan 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 22,000
- Estimated value
- Report date
- 05 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Bolt Biotherapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 22,000
- Estimated value
- Report date
- 12 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Rapport Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 21,850
- Estimated value
- Report date
- 17 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
ArriVent Biopharma, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 30 Jan 2024
- Price
- Ownership
- Sofinnova Venture Partners XI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
BioAge Labs, Inc.
- Security class
- Series D Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 27 Sep 2024
- Price
- Ownership
- Sofinnova Venture Partners XI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
CinCor Pharma, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 28 Nov 2022
- Price
- $28.75
- Ownership
- By Sofinnova Synergy Master Fund, LP
Form 4 holding
Director, 10%+ Owner
CinCor Pharma, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 24 Feb 2023
- Price
- $28.75
- Ownership
- By Sofinnova Venture Partners X, L.P.
Form 4 holding
Director, 10%+ Owner
CinCor Pharma, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 24 Feb 2023
- Price
- $28.75
- Ownership
- Direct
Form 4 holding
Director
Seaport Therapeutics, Inc.
- Security class
- Series A-2 Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- By Sofinnova Venture Partners XI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Seaport Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- By Sofinnova Venture Partners XI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Y-mAbs Therapeutics, Inc.
- Security class
- Employee Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by James Healy
4
SPTX
Seaport Therapeutics, Inc.
- Report period
- 04 May 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 04 May 2026, 18:14
- Role
- Director
- Next action
- Open filing details
3
SPTX
Seaport Therapeutics, Inc.
- Report period
- 30 Apr 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 30 Apr 2026, 20:10
- Role
- Director
- Next action
- Open filing details
4
YMAB
Y-mAbs Therapeutics, Inc.
- Report period
- 16 Sep 2025
- Transactions
- 11
- Transaction value
- -$19,142,577
- Accepted by SEC
- 18 Sep 2025, 20:59
- Role
- Director
- Next action
- Open filing details
4
YMAB
Y-mAbs Therapeutics, Inc.
- Report period
- 30 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2025, 16:20
- Role
- Director
- Next action
- Open filing details
4
RAPP
Rapport Therapeutics, Inc.
- Report period
- 17 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
BIOA
BioAge Labs, Inc.
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2025, 16:46
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 25 Apr 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 Apr 2025, 20:35
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 31 Jan 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Feb 2025, 21:15
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 25 Oct 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 Oct 2024, 21:05
- Role
- Director
- Next action
- Open filing details
4
BIOA
BioAge Labs, Inc.
- Report period
- 25 Sep 2024
- Transactions
- 8
- Transaction value
- +$11,999,970
- Accepted by SEC
- 27 Sep 2024, 16:22
- Role
- Director
- Next action
- Open filing details
3
BIOA
BioAge Labs, Inc.
- Report period
- 25 Sep 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 25 Sep 2024, 16:53
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 26 Jul 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Jul 2024, 21:05
- Role
- Director
- Next action
- Open filing details
4
RAPP
Rapport Therapeutics, Inc.
- Report period
- 01 Jul 2024
- Transactions
- 12
- Transaction value
- +$1,079,575
- Accepted by SEC
- 03 Jul 2024, 20:04
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 28 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2024, 21:05
- Role
- Director
- Next action
- Open filing details
4
BOLT
Bolt Biotherapeutics, Inc.
- Report period
- 12 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2024, 18:50
- Role
- Director
- Next action
- Open filing details
4
YMAB
Y-mAbs Therapeutics, Inc.
- Report period
- 11 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2024, 21:01
- Role
- Director
- Next action
- Open filing details
4
RAPP
Rapport Therapeutics, Inc.
- Report period
- 10 Jun 2024
- Transactions
- 7
- Transaction value
- +$9,500,008
- Accepted by SEC
- 10 Jun 2024, 19:38
- Role
- Director
- Next action
- Open filing details
3
RAPP
Rapport Therapeutics, Inc.
- Report period
- 06 Jun 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2024, 19:03
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 26 Apr 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Apr 2024, 20:35
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 18 Mar 2024
- Transactions
- 9
- Transaction value
- -$472,763,849
- Accepted by SEC
- 18 Mar 2024, 16:30
- Role
- Director
- Next action
- Open filing details
4
AVBP
ArriVent Biopharma, Inc.
- Report period
- 30 Jan 2024
- Transactions
- 3
- Transaction value
- +$7,999,992
- Accepted by SEC
- 31 Jan 2024, 16:10
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 26 Jan 2024
- Transactions
- 1
- Transaction value
- +$16,841
- Accepted by SEC
- 30 Jan 2024, 20:05
- Role
- Director
- Next action
- Open filing details
3
AVBP
ArriVent Biopharma, Inc.
- Report period
- 25 Jan 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 25 Jan 2024, 20:37
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 13 Dec 2023
- Transactions
- 1
- Transaction value
- -$37,835,000
- Accepted by SEC
- 22 Dec 2023, 14:21
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 27 Oct 2023
- Transactions
- 1
- Transaction value
- +$16,870
- Accepted by SEC
- 31 Oct 2023, 21:05
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 28 Jul 2023
- Transactions
- 1
- Transaction value
- +$15,901
- Accepted by SEC
- 01 Aug 2023, 21:05
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 30 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2023, 21:05
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 20 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2023, 16:16
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 14 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 20:56
- Role
- Director
- Next action
- Open filing details
4
BOLT
Bolt Biotherapeutics, Inc.
- Report period
- 12 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2023, 17:14
- Role
- Director
- Next action
- Open filing details
4
YMAB
Y-mAbs Therapeutics, Inc.
- Report period
- 08 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2023, 18:00
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 25 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 30 May 2023, 17:05
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 14 Apr 2023
- Transactions
- 1
- Transaction value
- +$15,598
- Accepted by SEC
- 18 Apr 2023, 20:10
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 13 Jan 2023
- Transactions
- 1
- Transaction value
- +$15,604
- Accepted by SEC
- 18 Jan 2023, 20:35
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 12 Jan 2023
- Transactions
- 3
- Transaction value
- -$1,204,771
- Accepted by SEC
- 17 Jan 2023, 19:43
- Role
- Director
- Next action
- Open filing details
4
CinCor Pharma, Inc.
- Report period
- 28 Nov 2022
- Transactions
- 4
- Transaction value
- -$85,920
- Accepted by SEC
- 27 Feb 2023, 20:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 16 Nov 2022
- Transactions
- 1
- Transaction value
- -$90,498
- Accepted by SEC
- 18 Jan 2023, 10:12
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 14 Oct 2022
- Transactions
- 1
- Transaction value
- +$15,624
- Accepted by SEC
- 18 Oct 2022, 21:07
- Role
- Director
- Next action
- Open filing details
4
CinCor Pharma, Inc.
- Report period
- 11 Aug 2022
- Transactions
- 2
- Transaction value
- +$15,180,000
- Accepted by SEC
- 15 Aug 2022, 15:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 05 Aug 2022
- Transactions
- 2
- Transaction value
- +$520,000
- Accepted by SEC
- 08 Aug 2022, 17:43
- Role
- Director
- Next action
- Open filing details
4
CinCor Pharma, Inc.
- Report period
- 05 Aug 2022
- Transactions
- 2
- Transaction value
- +$399,990
- Accepted by SEC
- 08 Aug 2022, 12:57
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
YMAB
Y-mAbs Therapeutics, Inc.
- Report period
- 15 Jul 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Jul 2022, 13:22
- Role
- Director
- Next action
- Open filing details
4/A
NTRA
Natera, Inc.
- Report period
- 08 Jul 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Sep 2022, 20:05
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 29 Jun 2022
- Transactions
- 6
- Transaction value
- +$14,736,158
- Accepted by SEC
- 01 Jul 2022, 13:23
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 15 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2022, 16:29
- Role
- Director
- Next action
- Open filing details
4
BOLT
Bolt Biotherapeutics, Inc.
- Report period
- 10 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 18:13
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 27 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Jun 2022, 21:05
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 25 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 May 2022, 21:46
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 01 Apr 2022
- Transactions
- 1
- Transaction value
- +$6,081
- Accepted by SEC
- 14 Apr 2022, 16:46
- Role
- Director
- Next action
- Open filing details
4
BOLT
Bolt Biotherapeutics, Inc.
- Report period
- 24 Mar 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 28 Mar 2022, 15:18
- Role
- Director
- Next action
- Open filing details
4
CinCor Pharma, Inc.
- Report period
- 11 Jan 2022
- Transactions
- 4
- Transaction value
- +$5,200,000
- Accepted by SEC
- 13 Jan 2022, 15:33
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4/A
CHRS
Coherus BioSciences, Inc.
- Report period
- 07 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Feb 2022, 15:14
- Role
- Director
- Next action
- Open filing details
3
CinCor Pharma, Inc.
- Report period
- 06 Jan 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2022, 19:53
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CHRS
Coherus BioSciences, Inc.
- Report period
- 27 Sep 2021
- Transactions
- 3
- Transaction value
- -$7,250,063
- Accepted by SEC
- 29 Sep 2021, 20:18
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 22 Jul 2021
- Transactions
- 1
- Transaction value
- +$271,200
- Accepted by SEC
- 26 Jul 2021, 18:11
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 02 Jul 2021
- Transactions
- 1
- Transaction value
- +$74,923
- Accepted by SEC
- 07 Jul 2021, 18:48
- Role
- Director
- Next action
- Open filing details
4
Karuna Therapeutics, Inc.
- Report period
- 16 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2021, 16:31
- Role
- Director
- Next action
- Open filing details
4
NTRA
Natera, Inc.
- Report period
- 28 May 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2021, 20:05
- Role
- Director
- Next action
- Open filing details
4
YMAB
Y-mAbs Therapeutics, Inc.
- Report period
- 10 Jun 2020
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2021, 17:04
- Role
- Director
- Next action
- Open filing details